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OBJECTIVE — In this investigation we evaluated nine metabolic indexes from intravenous
glucose tolerance tests (IVGTTs) and oral glucose tolerance tests (OGTTs) in an effort to deter-
mine their prognostic performance in predicting the development of type 1 diabetes in those
with moderate risk, as deﬁned by familial relation to a type 1 diabetic individual, a positive test
for islet cell antibodies and insulin autoantibody, but normal glucose tolerance.
RESEARCH DESIGN AND METHODS — Subjects (n  186) who had a projected risk
of 25–50% for developing type 1 diabetes within 5 years were followed until clinical diabetes
onset or the end of the study as part of the Diabetes Prevention Trial–Type 1. Prognostic
performance of the metabolic indexes was determined using receiver operating characteristic
(ROC) curve and survival analyses.
RESULTS — Two-hour glucose from an OGTT most accurately predicted progression to
disease compared with all other metabolic indicators with an area under the ROC curve of 0.67
(95% CI 0.59–0.76), closely followed by the ratio of ﬁrst-phase insulin response (FPIR) to
homeostasis model assessment of insulin resistance (HOMA-IR) with an area under the curve
value of 0.66. The optimal cutoff value for 2-h glucose (114 mg/dl) maintained sensitivity and
speciﬁcityvalues0.60.Thehazardratioforthosewith2-hglucose114mg/dlcomparedwith
those with 2-h glucose 114 mg/dl was 2.96 (1.67–5.22).
CONCLUSIONS — The ratio of FPIR to HOMA-IR from an IVGTT provided accuracy in
predicting the development of type 1 diabetes similar to that of 2-h glucose from an OGTT,
which, because of its lower cost, is preferred. The optimal cutoff value determined for 2-h
glucose provides additional guidance for clinicians to identify subjects for potential prevention
treatments before the onset of impaired glucose tolerance.
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E
arly disease prediction and preven-
tion are some of the most important
strategiesinhealthcare.Preventative
care can substantially decrease mortality
and morbidity and signiﬁcantly reduce
public health costs (1,2). As genetic/
familial factors and autoimmune factors
have become available to screen subjects
for the risk of developing type 1 diabetes,
early intervention trials for this disease
have become a reality (3–7). The charac-
terization of this risk may be reﬁned by
additional factors to more precisely target
individuals who would beneﬁt from pre-
ventative treatment. To most accurately
select individuals who are at risk for de-
veloping disease, beyond screening for
antibodies and genetic factors, metabolic
risk indicators are being investigated for
the development of a more effective clin-
ical prognostic index (8–12).
The principal metabolic indexes cur-
rently being evaluated as prognostic indi-
cators for type 1 diabetes have been
focused on measurements from oral glu-
cose tolerance tests (OGTTs) and intrave-
nous glucose tolerance tests (IVGTTs).
Previous research from the Diabetes Pre-
vention Trial–Type 1 (DPT-1) has indi-
cated that some metabolic indexes
derived from an OGTT provide substan-
tial predictive value in receiver operating
characteristic (ROC) area under the curve
(AUC) analysis (13). IVGTT-derived in-
dexes, such as ﬁrst-phase insulin re-
sponse (FPIR), homeostasis model
assessment of insulin resistance (HOMA-
IR), and FPIR-to–HOMA-IR ratio have
also demonstrated prognostic value (14–
16). However, indexes from both methods
havenotbeencomparedforpredictiveac-
curacy in moderate-risk subjects who are
antibody-positive and have genetic risk
factors but do not have impaired glucose
tolerance. Because subjects in this popu-
lation who would develop disease are in
an early stage of disease progression, they
are an important subgroup to target for
preventative intervention. If OGTT or
IVGTT measurements produce superior
predictive indexes compared with each
other,costsinfuturetrialscanbereduced
byrelyingonasinglemethodofmeasure-
mentthatproducesthegreatestpredictive
accuracy.
In addition to determining the supe-
rior testing method for producing predic-
tiveindexes(OGTTvs.IVGTT),therealso
remains a need to produce effective prog-
nostic thresholds to select between indi-
viduals who will progress to disease and
who will not, because screening tests for
familial, genetic, and immunoglobin risk
factors are not precise enough to accu-
rately select subjects, particularly those at
an early stage of disease progression who
do not exhibit impaired glucose toler-
ance. Future intervention trials will de-
pend on a reﬁned selection tool to choose
subjects for early intervention to ensure
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effects. Optimal cutoff values derived
from ROC AUC analysis from metabolic
indexes would provide valuable guidance
for clinicians and researchers in evaluat-
ing patient risk for progressing to type 1
diabetes by providing a threshold, above
which the risk is characterized with
greaterprecisionthanisprovidedbytheir
underlying risk factors.
In this investigation, we assessed the
prognostic accuracy of nine metabolic in-
dexes for predicting the progression to
clinical onset of type 1 diabetes over a
5-year period using the data from DPT-1.
The optimal cutoff values of metabolic
indexes were determined to provide
previously unavailable guidance to cli-
nicians and researchers in selecting pa-
tients likely to progress to disease, who
are therefore candidates for early pre-
ventative intervention.
RESEARCH DESIGN AND
METHODS— DPT-1 was a longitudi-
nal study in North America, which was
designed to determine whether type 1 di-
abetes can be prevented or delayed by
preclinical intervention of an oral insulin
supplement. DPT-1 screened for islet cell
antibody(ICA)positivityin103,390ﬁrst-
and second-degree nondiabetic relatives
of individuals in whom type 1 diabetes
had been diagnosed before the age of 45
years. The 3,483 relatives positive for
ICAs were staged to quantify the pro-
jected5-yearriskofdiabetes(17).Staging
consisted of ICA conﬁrmation, HLA-DQ
typing,determinationofinsulinautoanti-
body (IAA), an IVGTT, and an OGTT.
A total of 372 subjects whose 5-year
risk was considered to be 25–50%, with-
out metabolic abnormality or loss of the
FPIR (deﬁned as moderate risk), were en-
tered into the DPT-1 oral insulin trial. To
study the natural history of the disease,
the current investigation evaluated 186
subjects who were randomly assigned to
the placebo arm of the study. All subjects
were examined every 6 months from en-
rollmentuntildiabetesonsetorstudyend
after randomization. All subjects (and/or
their parent) signed a written consent
form approved by the participating study
center’s human subjects committee.
Laboratory measurements
An IVGTT was performed after an over-
nightfast.TheIVGTTwasdoneasrecom-
mended by the ICARUS Study Group.
This recommendation includes instruc-
tions for a diet containing at least 150 g of
carbohydrate/day for the 3 days before
the test. Blood samples for determination
of glucose and insulin levels were drawn
at 10 and 4 min. A solution of 25%
dextrose (0.5 g/kg body wt up to a maxi-
mumof35g)wastheninfusedover3min
(15 s). Repeat blood samples for deter-
mination of glucose and insulin levels
were drawn at 1, 3, 5, 7, and 10 min after
the glucose infusion. FPIR was calculated
as the sum of the serum insulin concen-
trations at 1 and 3 min after intravenous
injection of glucose. FPIR was above
thresholdif10thpercentileforsiblings,
offspring, and second-degree relatives
(100 U/ml if aged 8 years and 60
U/ml if aged 8 years) and 1st per-
centile for parents (60 U/ml). These
thresholds were determined from the
Gainesville, Florida, Family Study and a
general school population study (18).
FPIR above threshold was required for el-
igibility. HOMA-IR was calculated as the
fastinginsulin(milliunitsperliter)fast-
ing glucose (millimoles per liter)/22.5
from the mean of fasting insulin at 4 and
10minandfastingglucoseat4minbefore
each IVGTT was performed.
OGTTs were administered to assess
glycemic status. The dose of oral glucose
was 1.75 g/kg (maximum, 75 g of carbo-
hydrate). Blood samples were obtained
forC-peptidemeasurementsinthefasting
state and at then 30, 60, 90, and 120 min
after oral glucose. Peak C-peptide was the
maximumpointofallmeasurements.The
AUC C-peptide was calculated using
the trapezoid rule. A normal OGTT dur-
ing staging was required for eligibility.
Diabetes was diagnosed according to
the American Diabetes Association crite-
ria: fasting glucose 126 mg/dl; 2-h glu-
cose 200 mg/dl with conﬁrmation by
either an elevated fasting or 2-h glucose
level at a follow-up visit; or random
plasma glucose 200 mg/dl accompa-
nied by symptoms of polyuria, polydip-
sia, and/or weight loss (19).
Statistical methods
For baseline characteristics, categorical
variables were compared by a Pearson 
2
test, and continuous variables were eval-
uatedbyttestforthedifferencesinmeans
or by the Wilcoxon rank-sum test for dif-
ferences in order between progressors
and nonprogressors. ROC curves were
usedtocomparethediscriminativepower
ofninedifferentmetabolicindexestopre-
dict progression to type 1 diabetes. The
global performance of each measurement
in predicting progression to type 1 diabe-
tes was summarized by the AUC, and re-
sults are presented as the mean (95% CI).
CIs that exclude 0.5 were considered to
indicate signiﬁcant results (20). ROC
AUCswerecomparedusingthealgorithm
suggestedbyDelongetal.(21),whichisa
nonparametricapproachtotheanalysisof
areas under correlated ROC curves by us-
ing the theory on generalized U-statistics
to generate an estimated covariance ma-
trix. The ROC curve is constructed by
varying the cut point used to determine
which values of the observed variable will
be considered abnormal and then plot-
ting the resulting sensitivities against the
corresponding false-positive rates (1 
speciﬁcity). The optimal cutoff points are
the values yielding maximum sums of
sensitivity and speciﬁcity from the ROC
curves. The Cox proportional hazards
model was used to calculate the hazard
ratio. The log-rank test was used for sur-
vival curves comparison. Analyses were
performedbyusingSAS(version9.2;SAS
Institute, Cary, NC) software.
RESULTS— A summary of clinical
and metabolic characteristics comparing
those who progressed to clinical disease
onset and those who did not is shown in
Table 1. By design, subjects were ICA
	
andIAA
	withanormalFPIRandnormal
glucose tolerance (n  186), giving them
a projected risk of 2550% for progres-
sion to clinical diabetes over 5 years. The
actualriskwas35%over5years.Thesub-
jects were followed for a median of 1,213
days (3.3 years; interquartile range 726–
1,718). Annual rate of loss to follow-up
was 0.2%. The subjects who were lost to
follow-up before the end of the study
were considered to be nonprogressors.
The progressors and nonprogressors did
not signiﬁcantly differ in age, sex, race, or
relationship to the proband.
The ROC AUCs of various metabolic
indexes for the prediction of progression
to type 1 diabetes are summarized in Ta-
ble 2. Fasting glucose from both IVGTTs
andOGTTsperformedpoorlyanddidnot
demonstrate prognostic ability with the
same AUC value of 0.49 (95% CI 0.40–
0.59). Analysis of IVGTT fasting insulin
demonstratedsomeprognosticvaluewith
an AUC value of 0.59 (0.5 – 0.68) al-
thoughtheestimatehadborderlinesignif-
icance. The AUC estimate of HOMA-IR
and FPIR exceeded 0.5, although the
lower conﬁdence limit for both variables
fell slightly below 0.5 at 0.49 and 0.48,
respectively, rendering them nonsigniﬁ-
cant predictors. However, when the ratio
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sulted in an AUC value of 0.66 (0.57–
0.74), representing the best index among
the indexes derived from IVGTTs. The
only statistically signiﬁcant AUC among
the standard indexes derived from OGTT
testingwas2-hglucose,whichyieldedthe
greatest AUC value at 0.67 (0.59–0.76)
of all metabolic indexes examined (Fig.
1). A composite index that included AUC
glucose and peak C-peptide was devel-
oped, using the proportional hazard
model [index  3.54  10
–4 (AUC glu-
cose)  0.15  (peak C-peptide)]. The
ROCAUCresultfortheOGTTcomposite
index was 0.71 (0.63–0.79). Although
higher than the FPIR-to–HOMA-IR ratio
and the 2-h glucose, the differences were
not signiﬁcant. The prediction perfor-
manceofantibodytiterswasevaluatedfor
comparison. AUCs for ICA titer and IAA
titer were 0.69 (0.61–0.77) and
0.67(0.58–0.76), respectively. They did
not provide better prediction than 2-h
glucose or the FPIR-to–HOMA-IR ratio
(P  0.05) in this population.
The cutoff values for optimal predic-
tion of progression to type 1 diabetes us-
ingROCanalysisforallmetabolicindexes
aresummarizedinTable2AlthoughFPIR
demonstrated high sensitivity (0.76) at
the optimal cutoff value, the low speciﬁc-
ity (0.40) depreciates FPIR as a useful
prognostic index. Optimal cutoff values
for fasting insulin and AUC C-peptide
also had high positive predictive ability
with sensitivities 0.80 but were lacking
in speciﬁcity, similar to FPIR, which re-
stricts them from being useful prognostic
indexes in this moderate-risk group. The
FPIR-to–HOMA-IR ratio and 2-h glucose
OGTT produced cutoff values with both
sensitivity and speciﬁcity levels 0.6,
demonstrating the greatest potential as
prognostic indexes compared with all
other metabolic indexes. The positive
predictive value (PPV) was 0.46 and 0.41
for 2-h glucose and FPIR-to–HOMA-IR
ratio, respectively. The negative predic-
tive value (NPV) was 0.83 for both
indexes.
Theoptimalcutoffvalueof114mg/dl
for OGTT 2-h glucose was notably less
thanthevaluecurrentlyusedtodeﬁnethe
lowerrangeofimpairedglucosetolerance
(140 mg/dl). The hazard ratio for those
with 2-h glucose equal to or in excess of
the optimal cutoff value (114) compared
with those less than the optimal cutoff
was 2.96 (95% CI 1.67–5.22) after ad-
justmentforage,sex,andBMI.The5-year
riskforthosewithbaselinevaluesequalto
Table 1—Clinical and metabolic characteristics of the study subjects
Characteristic Progressor Nonprogressor P value
n 53 (28) 133 (72)
Age (years) 9.78  6.35 12.79  9.23 0.67
BMI z score* 0.67 (1.56 to 0.53) 1.10 (2.61 to 0.33) 0.07
Race 0.64
White 47 (88.68) 116 (89.23)
African American 0 (0.00) 2 (1.54)
Hispanic 4 (7.55) 10 (7.69)
Other 2 (3.77) 2 (1.54)
Sex 0.53
Male 28 (52.83) 77 (57.89)
Female 25 (47.17) 56 (42.11)
Relationship to patient with
diabetes
0.09
Sibling 36 (67.92) 72 (54.14)
Offspring 15 (28.30) 38 (28.57)
Parent 1 (1.89) 6 (4.51)
Second-degree 1 (1.89) 17 (12.78)
Immunological factors
ICA titer (JDF units) 160.00 (80.00–320.00) 80.00 (20.00–160.00) 0.001
IAA titer (nU/ml) 385.10 (125.40–672.00) 156.70 (73.70–343.00) 0.001
ICA512 antibodies 0.01
Positive 32 (64.00) 50 (42.37)
Negative 18 (36.00) 68 (57.63)
GAD antibodies 0.674
Positive 38 (76.00) 86 (72.88)
Negative 12 (24.00) 32 (27.12)
Metabolic factors
IVGTT
Fasting glucose (mmol/l) 87.66  9.54 87.12  9.18 0.67
Fasting insulin (mU/l) 17.02  10.07 14.84  9.50 0.17
FPIR (l/ml) 145.22  80.49 163.90  105.84 0.2
HOMA-R 3.79  2.69 3.25  2.20 0.16
FPIR-to–HOMA-IR ratio 44.28  19.20 59.93  36.58 0.001
OGTT
Fasting glucose (mg/dl) 86.26  7.69 86.18  7.85 0.95
2-h glucose (mg/dl) 113.25  18.71 102.75  19.17 0.001
Peak C-peptide (nmol/l) 5.09  1.98 5.59  2.26 0.16
AUC C-peptide (nmol/l) 472.13  172.51 523.96  21.698 0.12
Data are n (%), mean  SD, or median (interquartile range). *BMI z score from 2000 Centers for Disease
Control and Prevention growth chart. JDF, Juvenile Diabetes Foundation.
Table 2—AUC, speciﬁcity, sensitivity, PPV, and NPV at the optimal cutoff value
Index/testing AUC (95% CI)
Optimal
cutoff Sensitivity Speciﬁcity PPV NPV
IVGTT
Fasting glucose 0.49 (0.40–0.59) 96 0.23 0.88 0.46 0.74
Fasting insulin 0.59 (0.50–0.68) 10.23 0.82 0.29 0.32 0.8
FPIR 0.57 (0.48–0.66) 156 0.76 0.4 0.34 0.81
HOMA-IR 0.58 (0.49–0.67) 2.64 0.66 0.48 0.33 0.77
FPIR-to-HOMA-IR ratio* 0.66 (0.57–0.74) 49.22 0.68 0.61 0.41 0.83
OGTT
Fasting glucose 0.49 (0.40–0.59) 88 0.47 0.56 0.27 0.7
2-h glucose 0.67 (0.59–0.76) 114 0.62 0.71 0.46 0.83
Peak C-peptide 0.56 (0.47–0.66) 5.3 0.7 0.46 0.34 0.79
AUC C-peptide 0.56 (0.47–0.65) 595 0.81 0.31 0.33 0.8
*AUCs are signiﬁcantly better than AUC fasting glucose derived from an IVGTT or OGTT (P  0.01).
Predictive accuracy of various metabolic indexes
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cutoff level was 46% compared with 17%
forthosewithbaselinevalueslessthanthe
optimal cutoff. The hazard ratio for those
undertheoptimalcutoffleveloftheFPIR-
to–HOMA-IR ratio (49.22) compared
with those equal to or in excess of the
optimal cutoff level of the FPIR-to–
HOMA-IR ratio (49.22) was 2.94
(1.62–5.35) after adjustment for age, sex,
and BMI. The 5-year risk for those with
baselinevaluesequaltoorinexcessofthe
optimal FPIR-to–HOMA-IR ratio cutoff
level was 41 with to 17% for those with
baseline values less than the optimal cut-
off. Kaplan-Meier curves (supplementary
Figs. A1 and A2, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc10-0802/DC1) illus-
trate the risk of diabetes over the study
period by the level of OGTT 2-h glucose
(P  0.001) and the level of IVGTT FPIR-
to–HOMA-IR ratio (P  0.001).
CONCLUSIONS — The comprehen-
sive baseline data from DPT-1 has pro-
vided the opportunity to assess and
validate the accuracy of metabolic risk in-
dicators in predicting the future develop-
ment of type 1 diabetes. Elevated fasting
glucose and substantially impaired glu-
cose tolerance are the primary metabolic
indicatorscurrentlyusedtoidentifythose
with signiﬁcant risk for progressing to
type1diabetes;however,theseindicators
cannot be used to effectively predict dis-
ease progression among individuals who
hadnotdemonstratedgrossmetabolicab-
normality. To generate accurate prognos-
tic indexes for those with such moderate
risk factors, in the current investigation
we evaluated nine metabolic indicators
for their prediction accuracy associated
with the following underlying risk fac-
tors: being a relative without impaired
glucose tolerance of an individual with
type 1 diabetes and having ICA/IAA pos-
itivity. The results of this investigation
identiﬁed two metabolic indicators as
having a signiﬁcant predictive accuracy
for identifying individuals likely to
progress to clinical onset of type 1 diabe-
teswithin5years:theFPIR-to–HOMA-IR
ratio and 2-h postprandial glucose.
Investigations into the progression of
type 2 diabetes have shown that insulin
resistance is demonstrated long before
overt diabetes is diagnosed and that this
can be a powerful predictor of disease
progression (20–23). Abdul-Ghani et al.
(22) investigated the prognostic perfor-
mance of insulin secretion/insulin resis-
tance indexes using ROC analysis to
determine their predictive accuracy for
progression to type 2 diabetes and re-
portedthatinsulinsecretion/insulinresis-
tance is the best predictor of type 2
diabetesdemonstratedbysubstantialsen-
sitivity and speciﬁcity. In the current in-
vestigation,theroleofinsulinresistanceis
alsoimpliedfromtheanalysisoftheFPIR-
to–HOMA-IR ratio, which demonstrated
signiﬁcant predictive accuracy in the
study population, with an AUC cutoff
pointthatmaintained0.68sensitivityand
0.61 speciﬁcity for detecting progression
to clinical onset. The etiological signiﬁ-
cance of this observation is the indication
thattheearlystagesoftype1diabetesmay
be demarcated by a disturbance in the
balance between insulin response and in-
sulin activity, although the effects of an
insulin secretion/insulin resistance dis-
turbance may be more subtle in type 1
diabetes progression (24). The counter-
regulatory hormones associated with pu-
bertymayplayaroleinthemodulationof
insulin secretion and insulin resistance
during this developmental period
(24,25).
The clinical utility of the FPIR-to–
HOMA-IRratiomustbeconsideredinthe
context of the predictive accuracy found
in a standard index derived from an
OGTT,atestthatisbothlessburdensome
tothepatientand,insomeinstances,may
be administered at lower cost. The FPIR-
to–HOMA-IRratioisactuallyacomposite
of three measures: two from an IVGTT to
determine FPIR and a fasting status mea-
surement to determine HOMA-IR. In
contrast, the relatively simplistic 2-h
Figure 1—ROC AUC for various metabolic indexes. F, 2-h glucose–OGTT; E, FPIR; ‚, FPIR-to–HOMA-IR ratio;  , HOMA-IR.
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maintained the largest ROC AUC and the
greatest degree of both sensitivity and
speciﬁcity at the optimal cutoff value
compared with all other metabolic indi-
cators evaluated in this investigation. In
addition, when compared at the same
NPV, 2-h glucose retained a higher esti-
mated PPV than the FPIR-to–HOMA-IR,
although this difference was not statisti-
cally signiﬁcant. However, because
HOMA-IRdoesnotrequireanIVGTT,fu-
ture research may indicate that insulin re-
sistance can be incorporated as a part of a
composite to increase predictive value.
The OGTT is the gold standard
method to diagnose type 1 diabetes and
impaired glucose tolerance. A standard
2-h glucose tolerance test contributes
substantial predictive accuracy beyond
screening for the underlying risk factors.
This result is consistent with the ﬁndings
by Sosenko et al. (13), who determined
that the accuracy of 2-h glucose was 0.66
for the combined study population of
subjects with and without impaired glu-
cose tolerance at baseline (13). The prog-
nostic accuracy of this index is probably
due to 2-h glucose being inﬂuenced by
insulinproductionandinsulinresistance,
two important factors that modulate the
progressionofthisdisease.Thisﬁndingis
evidenced by an observed level of prog-
nostic accuracy similar to the FPIR-to–
HOMA-IR ratio. Because a principal
objective of this investigation was to ex-
amine metabolic indexes to provide clin-
ical guidance for selecting individuals at
high risk for progression to disease de-
spite the absence of clinical metabolic ab-
normality, we have determined the
optimal cutoff point for the metabolic in-
dex with the largest ROC AUC, 2-h glu-
cose at 114 mg/dl. This threshold derived
from standard OGTT diagnostics may
provide cost-effective guidance for clini-
cians and researchers for selecting pa-
tients likely to progress to disease if not
provided preventative care, even among
those presenting with normal glucose tol-
erance, in future prevention trials.
This investigation contributes to a
growing body of evidence that metabolic
indexes derived from OGTT testing are
the most efﬁcient and effective analytical
method of determining the risk for pro-
gression to type 1 diabetes in those with
known genetic and autoimmune risk fac-
tors(9,13).MeasurementsfromanOGTT
are the clinical standard for diagnosing
impaired glucose tolerance and clinical
diabetes and are therefore a necessary
componentinevaluatingsubjectsfortype
1diabetes.Intheabsenceofsuperiorpre-
dictive value from indexes produced by
IVGTT measurements, IVGTT essentially
replicates the results from OGTT mea-
surements. Future intervention trials may
consider elimination of IVGTT measure-
ments as an effective cost-reduction
strategy.
The success of preventative medicine
is dependent on accurate identiﬁcation of
patientswithriskfordiseasedevelopment
at an early stage of disease progression. In
thisinvestigation,weanalyzedthepredic-
tion accuracy of nine common and novel
metabolic indicators for identifying pa-
tientswithmoderateriskfactors,whodis-
play no clinical metabolic abnormality as
yet and who progress to type 1 diabetes
within 5 years. Both the FPIR-to–
HOMA-IR ratio from the IVGTT and the
2-h glucose from the OGTT provided sig-
niﬁcant prognostic value. The standard
OGTT index of 2-h glucose is preferred
because it achieved the largest prognostic
accuracy in predicting disease onset,
making the FPIR-to–HOMA-IR ratio a re-
dundant and unnecessary predictive in-
dex. In addition, our ﬁndings conﬁrm
prior DPT-1 ﬁndings that accuracy for se-
lectingat-riskpatientscouldbeimproved
by using 2-h glucose values below the
current cutoff for impaired glucose toler-
ance. Future analysis should focus on the
combination of metabolic markers, im-
munological markers, and/or genetic
markers to improve the modest PPVs de-
rivedfromsolitarypredictors.Ourresults
indicatedthatautoantibodytitersmaynot
provide a cost-beneﬁt improvement over
OGTTs as a sole predictor, but they may
be an important component of a compos-
ite modeled score. This is a secondary
analysis of DPT-1 data with the sample
size limited to the placebo arm of the oral
insulin protocol. Nonetheless, it provides
much needed guidance for clinicians and
researchersforselectingsubjectsinfuture
prevention trials in populations with un-
derlying risk factors and clinically normal
glucose tolerance by providing both the
evidence for a preferred index and a
threshold for selection.
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